ArticleJournal of perinatology : official journal of the California Perinatal Association2025
End-tidal carbon monoxide for routine monitoring of significant hemolysis in the management of newborn hyperbilirubinemia.
Article in Journal of perinatology : official journal of the California Perinatal Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The prediction of phototherapy by early postnatal ETCOc in Chinese newborns.BMC pediatrics · 2025Trial
- Hemolytic hyperbilirubinemia.Journal of perinatology : official journal of the California Perinatal Association · 2026Article
- End tidal carbon monoxide and significant hemolysis.Journal of perinatology : official journal of the California Perinatal Association · 2026Review
- Can age-specific ETCOc determination predict the need for neonatal phototherapy?Pediatric research · 2026Article
- Kernicterus Continues to Occur in the USA Despite Concerted Preventive Efforts.Case reports in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAssess the efficacy of routine ETCOc for all newborns in managing neonatal hyperbilirubinemia. STUDY
designRetrospective chart review of 1029 consecutive well-baby nursery admissions following the 2022 AAP hyperbilirubinemia guidelines. Only ETCOc, not type, Rh, and DAT, was used to determine if significant hemolysis was present in sufficient degree to affect bilirubin management. A cost-benefit analysis comparing the two methods was conducted.
result2.8% of infants required phototherapy, and 1.1% were readmitted for hyperbilirubinemia. The closer an infant's bilirubin level was to the phototherapy threshold, the higher the ETCOc. 12 of 29 DAT negative infants with ETCOc ≥ 2.5 PPM who received phototherapy would have gone home with significant hemolysis at risk for readmission or kernicterus if not for the use of ETCOc.
conclusionETCOc is preferable for assessing significant hemolysis in the newborn, can be used to safely manage newborn hyperbilirubinemia, and results in cost savings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.